NCT05687188 · H. Lee Moffitt Cancer Center and Research Institute
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
What this study is about
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
View original scientific description
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
Interventions
OTHER
Blood Sample Collection
Participants will have 40 mL of blood drawn at baseline/pre-treatment. The study team will aim to have this blood collected at the time of standard of care blood draw if possible.
OTHER
Tissue Sample Collection
At the time of tissue biopsy or surgical resection (if applicable) pancreatic tumor tissue, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
OTHER
Data Collection
Participants will complete a study questionnaire at baseline that includes medical history, lifestyle, and family history information.
OTHER
Medical Image Collection
Medical images that are obtained during routine care such as computed tomography (CT) scans, magnetic resonance imaging (MRIs) and ultrasounds will be reviewed by the study team throughout the participant's medical care.
Primary outcome measures
Assess molecular and radiological landscape of traditional PDAC tumors in the context of Race/Ethnicity
Time frame: at 36 months
Investigators will compare gene prevalence, type and expression of genetic mutations and radiomic features in African American participants vs Non-Hispanic White participants
Compare biological properties of Adipose Tissue dysfunction
Time frame: at 36 months
Investigators will compare biological properties of Adipose Tissue dysfunction between African American vs Non-Hispanic White participants.
Examine the role of Adipose Tissue and PDAC tumor interactions in influencing tumor growth, metastasis, and therapeutic response
Time frame: at 36 months
Investigators will compare the biological interactions of Adipose Tissue and PDAC tumor growth between African American vs. Non-Hispanic White participants to develop new and/or targeted drug combinations.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Adults 18 years of age or older at time of signing informed consent
- Patients who self-report as African American, Non-Hispanic White
- Patients who present to the gastrointestinal (GI) clinic, surgery, or endoscopy at a participating Florida Pancreas Collaborative (FPC) site or the University of Mississippi Medical Center (UMMC) with a clinical suspicion or diagnosis of a pancreatic tumor.
Exclusion criteria
- Patient under 18 years of age
- Has no suspicion or diagnosis of a pancreatic cancer or tumor
- Self-reported race/ethnicity other than African American or Non-Hispanic White.
Where
- Tampa, Florida
- Jackson, Mississippi
Collaborators
United States Department of Defense
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced May 26, 2026 · Source of record for eligibility and locations